Effect of somatostatin analogue octreotide in medulloblastoma in xenograft and cell culture study

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The effect and possible timing of nonradiolabeled somatostatin analogue octreotide are still not determined in the treatment of medulloblastoma, while the presence of somatostatin receptor type-2 (SSTR2) is proved in the majority of medulloblastoma by several authors. Procedures: Daoy, SSTR2A positive medulloblastoma cell culture was tested with octreotide in monotherapy and combined with cisplatin, etoposide, and vincristine. Daoy medulloblastoma mice xenograft was treated with octreotide alone. Results: In monolayer cell culture high-dose octreotide (44 M) resulted in mitotic inhibition with parallel increment of apoptosis. Combination with cytostatic drugs did not result in additive or synergistic effect, but vincristine was partially antagonized. In medulloblastoma xenograft, octreotide monotherapy (100 g/kg/day for 10 days) resulted in partial tumor growth inhibition. Conclusions: High concentration of nonradiolabeled octreotide may have role in the treatment of medulloblastoma by long-term administration. Concomitant administration of octreotide with widely used cytostatic drugs against medulloblastoma will not have beneficial impact.

Original languageEnglish
Pages (from-to)363-374
Number of pages12
JournalPediatric Hematology and Oncology
Volume26
Issue number5
DOIs
Publication statusPublished - Jul 2009

Fingerprint

Medulloblastoma
Octreotide
Somatostatin
Heterografts
Cell Culture Techniques
Cytostatic Agents
Vincristine
Etoposide
Cisplatin
Apoptosis
Growth

Keywords

  • Cell culture
  • Daoy
  • Medulloblastoma
  • Octreotide
  • Somatostatin receptor
  • SSTR2A
  • Targeted therapy
  • Xenograft

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

@article{e93aadeb092643ea81066a762b772849,
title = "Effect of somatostatin analogue octreotide in medulloblastoma in xenograft and cell culture study",
abstract = "Background: The effect and possible timing of nonradiolabeled somatostatin analogue octreotide are still not determined in the treatment of medulloblastoma, while the presence of somatostatin receptor type-2 (SSTR2) is proved in the majority of medulloblastoma by several authors. Procedures: Daoy, SSTR2A positive medulloblastoma cell culture was tested with octreotide in monotherapy and combined with cisplatin, etoposide, and vincristine. Daoy medulloblastoma mice xenograft was treated with octreotide alone. Results: In monolayer cell culture high-dose octreotide (44 M) resulted in mitotic inhibition with parallel increment of apoptosis. Combination with cytostatic drugs did not result in additive or synergistic effect, but vincristine was partially antagonized. In medulloblastoma xenograft, octreotide monotherapy (100 g/kg/day for 10 days) resulted in partial tumor growth inhibition. Conclusions: High concentration of nonradiolabeled octreotide may have role in the treatment of medulloblastoma by long-term administration. Concomitant administration of octreotide with widely used cytostatic drugs against medulloblastoma will not have beneficial impact.",
keywords = "Cell culture, Daoy, Medulloblastoma, Octreotide, Somatostatin receptor, SSTR2A, Targeted therapy, Xenograft",
author = "P. Hauser and Z. Hanz{\'e}ly and Domokos M{\'a}th{\'e} and Erika Szab{\'o} and G. Barna and A. Sebesty{\'e}n and A. Jeney and D. Schuler and G. Fekete and M. Garami",
year = "2009",
month = "7",
doi = "10.1080/08880010902973293",
language = "English",
volume = "26",
pages = "363--374",
journal = "Pediatric Hematology and Oncology",
issn = "0888-0018",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Effect of somatostatin analogue octreotide in medulloblastoma in xenograft and cell culture study

AU - Hauser, P.

AU - Hanzély, Z.

AU - Máthé, Domokos

AU - Szabó, Erika

AU - Barna, G.

AU - Sebestyén, A.

AU - Jeney, A.

AU - Schuler, D.

AU - Fekete, G.

AU - Garami, M.

PY - 2009/7

Y1 - 2009/7

N2 - Background: The effect and possible timing of nonradiolabeled somatostatin analogue octreotide are still not determined in the treatment of medulloblastoma, while the presence of somatostatin receptor type-2 (SSTR2) is proved in the majority of medulloblastoma by several authors. Procedures: Daoy, SSTR2A positive medulloblastoma cell culture was tested with octreotide in monotherapy and combined with cisplatin, etoposide, and vincristine. Daoy medulloblastoma mice xenograft was treated with octreotide alone. Results: In monolayer cell culture high-dose octreotide (44 M) resulted in mitotic inhibition with parallel increment of apoptosis. Combination with cytostatic drugs did not result in additive or synergistic effect, but vincristine was partially antagonized. In medulloblastoma xenograft, octreotide monotherapy (100 g/kg/day for 10 days) resulted in partial tumor growth inhibition. Conclusions: High concentration of nonradiolabeled octreotide may have role in the treatment of medulloblastoma by long-term administration. Concomitant administration of octreotide with widely used cytostatic drugs against medulloblastoma will not have beneficial impact.

AB - Background: The effect and possible timing of nonradiolabeled somatostatin analogue octreotide are still not determined in the treatment of medulloblastoma, while the presence of somatostatin receptor type-2 (SSTR2) is proved in the majority of medulloblastoma by several authors. Procedures: Daoy, SSTR2A positive medulloblastoma cell culture was tested with octreotide in monotherapy and combined with cisplatin, etoposide, and vincristine. Daoy medulloblastoma mice xenograft was treated with octreotide alone. Results: In monolayer cell culture high-dose octreotide (44 M) resulted in mitotic inhibition with parallel increment of apoptosis. Combination with cytostatic drugs did not result in additive or synergistic effect, but vincristine was partially antagonized. In medulloblastoma xenograft, octreotide monotherapy (100 g/kg/day for 10 days) resulted in partial tumor growth inhibition. Conclusions: High concentration of nonradiolabeled octreotide may have role in the treatment of medulloblastoma by long-term administration. Concomitant administration of octreotide with widely used cytostatic drugs against medulloblastoma will not have beneficial impact.

KW - Cell culture

KW - Daoy

KW - Medulloblastoma

KW - Octreotide

KW - Somatostatin receptor

KW - SSTR2A

KW - Targeted therapy

KW - Xenograft

UR - http://www.scopus.com/inward/record.url?scp=68449102191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68449102191&partnerID=8YFLogxK

U2 - 10.1080/08880010902973293

DO - 10.1080/08880010902973293

M3 - Article

VL - 26

SP - 363

EP - 374

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

SN - 0888-0018

IS - 5

ER -